Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Study to Evaluate the Safety, Efficacy and Pharmacokinetics of SPR001 (Tildacerfont) in Children Aged 2 to 17 Years With Congenital Adrenal Hyperplasia

Next Previous
X
Search
Trial Profile

A Phase 2 Study to Evaluate the Safety, Efficacy and Pharmacokinetics of SPR001 (Tildacerfont) in Children Aged 2 to 17 Years With Congenital Adrenal Hyperplasia

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tildacerfont (Primary)
  • Indications Congenital adrenal hyperplasia
  • Focus Adverse reactions
  • Acronyms CAHptain; CAHptain-205
  • Sponsors Spruce Biosciences

    • Most Recent Events

    • 13 May 2024 According to a Spruce Biosciences media release, End of Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) planned in the first quarter of 2025.
    • 13 May 2024 According to a Spruce Biosciences media release, additional Dose-Ranging Data from Adults and Children with CAH in CAHptain-205 Anticipated in Q3 2024
    • 13 May 2024 According to a Spruce Biosciences media release, Posters Highlighting Baseline Characteristics from the CAHmelia Program in Adult CAH and CAHptain-205 Study in Pediatric CAH Presented at the Pediatric Endocrine Society (PES) 2024 Annual Meeting

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top